Telomerase-dependent oncolytic adenovirus for cancer treatment

Gene Therapy

Volumn 10, Issue 15, 2003, Pages 1241-1247

  Huang, T G ^a   Savontaus, M J ^a   Shinozaki, K ^a   Sauter, B V ^a   Woo, S L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer gene therapy; Conditionally replicative adenovirus; Hepatocellular carcinoma; Telomerase reverse transcriptase

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC VIRUS; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TUMOR EXTRACT; VIRUS PROTEIN;

ADENOVIRUS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; FEMALE; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE SPECIFICITY; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CELL DEATH; CYTOPATHOGENIC EFFECT, VIRAL; DNA-BINDING PROTEINS; GENE TARGETING; GENE THERAPY; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); TELOMERASE; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MUS MUSCULUS;

EID: 0042674013     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301987     Document Type: Article

References (33)

1. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000; 19: 6660-6669.
2. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
3. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
4. Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nat Med 2000; 6: 1134-1139.
5. Reid Tet al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy 2001; 8: 1618-1626.
6. Leppard KN, Shenk T. The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism. EMBO 1989; 8: 2329-2336.
7. Shen Y et al. Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55 K protein. J Virol 2001; 75: 4297-4307.
8. Takahashi M et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002; 5: 627-634.
9. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
10. Yu DC et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-4203.
11. Yu DC et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
12. Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of Ela-deleted adenoviral vectors. Hum Gene Ther 2000; 11: 2009-2024.
13. De weese TL et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472.
14. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001; 10: 677-685.
15. Ulaner GA et al. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998; 58: 4168-4172.
16. Hara H et al. Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer. Lung Cancer 2001; 34: 219-226.
17. Kawakami Y et al. Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues. Oncogene 2000; 19: 3888-3893.
18. Rathi A et al. Telomerase RNA expression during progression of gastric cancer. Hum Pathol 1999; 30: 1302-1308.
19. Saito K et al. Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in breast cancer. Jpn J Cancer Res 2002; 93: 253-258.
20. Ito H et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 1998; 4: 2807-2810.
21. Takakura M et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-557.
22. Hahn WC et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-1170.
23. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Therapy 2002; 9: 30-37.
24. Majumdar AS et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Therapy 2001; 8: 568-578.
25. Savontaus MJ, Sauter BV, Huang TG, Woo SL. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Therapy 2002; 9: 972-979.
26. Goodwin EC, DiMaio D. Induced senescence in HeLa cervical carcinoma cells containing elevated telomerase activity and extended telomeres. Cell Growth Differ 2001; 12: 525-534.
27. Ogretmen B et al. Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line. J Biol Chem 2001; 276: 32506-32514.
28. Abdul-Ghani R et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000; 2: 539-544.
29. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002; 13: 1737-1750.
30. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
31. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
32. Lamont JP et al. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000; 7: 588-592.
33. Vasey PA et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562-1569.